🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection

RecruitingNAAges 18 Years - anyAllHospices Civils de Lyon
NCT03955172 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Background: Long-term success of organ transplantation is limited by the inexorable loss of graft function due to rejection. Prevalent dogma defends that allograft rejection is exclusively mediated by the adaptive immune system: T cells are responsible for cellular rejections and B cells producing Donor Specific Antibodies (DSA) are responsible for humoral rejection. Recently, we demonstrated that innate NK cells could be implicated in the generation of chronic vascular rejections lesions by sensing the absence of expression of self Major Histocompatibility Complex (MHC) class I molecules ("missing self") on graft endothelial cells with their Killer cell immunoglobulin-like (KIR) receptors. Using human in vitro and murine in vivo models, we also showed that Mammalian Target Of Rapamycin (mTOR) inhibitors could efficiently prevent this new kind of rejection. Objective: The aim of our p

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patient aged \> 18 years * Kidney transplanted patient * Having microvascular inflammation lesion on his graft biopsy associated to mild chronic lesions * In absence of donor specific antibodies * In presence of a missing self Exclusion Criteria: * Proteinuria/urinary creatinin \> 100 mg/mmol * Antecedent of poor tolerance or hypersensibility to everolimus or sirolimus * Severe chronic lesions * Presence of donor specific antibodies
💊

What it tests

  • Everolimus
📍

Where

1 site
Service de transplantation, néphrologie et immunologie clinique, Hôpital Edouard Herriot (HCL)
Lyon, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy